"Colorado Retina Associates is a 13 physician, 1 optometrist, sub-specialty eye care practice providing medical and surgical care of vitreo-retinal eye disease. We provide comprehensive treatment for age-related macular degeneration (AMD), diabetic retinopathy, retinal vascular disease, retinal detachments, ocular tumors, uveitis/inflammatory eye disease, inherited retinal degenerations (IRD's) and numerous other vitreoretinal conditions. Our group of retina and sub-specialists have trained at internationally renowned fellowship programs (6 or more years after medical school) and continue to engage in academia, advocacy, volunteering, and education both nationally and abroad."

During the past decade, Colorado Retina Associates PC conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 18 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 18 clinical trials were completed. i.e. 81.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Colorado Retina Associates PC" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Genentech, Inc." with 5 trials sponsored, "Kodiak Sciences Inc" with 5 trials sponsored, "Allergan" with 3 trials sponsored and "Clearside Biomedical, Inc." with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Colorado Retina Associates PC" #1 collaborator was "Foundation Fighting Blindness" with 2 trials as a collaborator, "National Eye Institute (NEI)" with 2 trials as a collaborator, "Alder Hey Children's NHS Foundation Trust" with 1 trials as a collaborator, "Cambridge University Hospitals NHS Foundation Trust" with 1 trials as a collaborator and "Children's Health" with 1 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Colorado Retina Associates PC" are "Geographic Atrophy" (12 trials), "Diabetic Macular Edema" (6 trials), "Macular Degeneration" (6 trials), "Macular Edema" (4 trials) and "Retinal Vein Occlusion" (3 trials). Many other conditions were trialed in "Colorado Retina Associates PC" in a lesser frequency.

Most popular intervention types in "Colorado Retina Associates PC" are "Drug" (48 trials), "Other" (16 trials), "Biological" (3 trials), "Procedure" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (16 trials), "Aflibercept" (9 trials), "Faricimab" (6 trials), "KSI-301" (5 trials) and "Ranibizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Colorado Retina Associates PC" are 55 trials for "All" genders.

Currently, there are NaN active trials in "Colorado Retina Associates PC". undefined are not yet recruiting, 3 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Colorado Retina Associates PC, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Colorado Retina Associates PC, 4 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".